Loading...

ONCO ONCONETIX INC Company Mergers 8-K Filing

NCNT

NC

ONCONETIX INC

(ONCO)

2025 8-K

Show Summary

Show Summary

Voluntary Delisting

Reverse Stock Split

Loan Defaults (Secured, Uns...

Delisting due to Non-Compli...

Business Combination

Management Changes

Clinical Data Release

Conference Announcement

Management Changes

Financial Agreement

Nasdaq Compliance Notice

Settlement Agreement

Asset Purchase Update

Auditor Resignation

Stock Split Update

Stock Split Action

Asset Purchase Agreement

Annual Meeting Results

Share Issuance Vote

Nasdaq Compliance Update

Shareholder Director Nomina...

Definitive Agreement

Appointment of Interim CFO

Management Change

Delisting Notice

Notice of Non-Compliance wi...

Amendment to Form 8-K

Amendment to Form 8-K/A

Appointment of Director

Appointment of Director

Investment Agreement

Departure of Directors or C...

Management Changes

Share Exchange Agreement

Share Exchange Agreement

Acquisition and Rebranding

Acquisition Announcement

Termination of Agreement

CEO and CFO Appointments

Distribution Agreement and ...

Resignation and Appointment

Agreement with Copay Consul...

Agreement for new preferred...

Agreement for PIO Exchange

Agreement with Knipper Health

Strategic Alliances

Asset Purchase Agreement

Board Decisions and Annual ...

Presentation at JMP Securit...

Conference Presentation

Asset Purchase Agreement

Agreement for Stock Sale

Financial Results Press Rel...

Annual Meeting and Stockhol...

Resignation and Appointment

Presentation at Biotech Sho...

Presentation Filing

External Links:

On April 8, 2025, Onconetix, Inc. announced a non-binding letter of intent for a business combination with Ocuvex Therapeutics, Inc., a biopharmaceutical company.

AI Assistant

ONCONETIX INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.